BARDA lacks cash to invest in the development of a new Covid-19 drug


gHello everyone and welcome to another week of work. We hope the weekend respite has been refreshing and relaxing, as here we are – once again – faced with the usual growing to-do list of online calls and deadlines etc. But you know, the world just keeps turning, so it’s time to give it that extra boost with a useful cup of stimulation. Our choice this morning is maple bourbon. Yes, it is a real thing. Do not hesitate to join us. In the meantime, here is some information to help you. Hope you have a pleasant day and keep in touch. …

Leaders of the world’s richest countries and several drugmakers have taken action to expand equitable access to Covid-19 vaccines, such as issuing voluntary licenses to expand manufacturing, increasing donations to a global distribution program, and investing in production capacity in Africa, STAT writes. But there was no consensus on the Rome Declaration on a proposal backed by the United States and dozens of low- and middle-income countries to issue a temporary waiver of intellectual property protections.

Unlock this article by subscribing to STAT + and enjoy your first 30 days free!


What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news from Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, as well as healthcare disruptions in Silicon Valley and beyond.

What is included?

  • Daily reporting and analysis
  • Industry’s most comprehensive coverage from a powerful team of journalists
  • Newsletters reserved for subscribers
  • Daily newsletters to keep you informed of the most important industry news of the day
  • STAT + conversations
  • Weekly opportunities to engage with our journalists and leading industry experts in live video chats
  • Exclusive industry events
  • Premium access to subscriber-only networking events nationwide
  • The best reporters in the industry
  • The most reliable and most connected newsroom in the healthcare industry
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.

Leave A Reply

Your email address will not be published.